Header Logo

Connection

WOLFGANG WINKELMAYER to Oligonucleotides

Back to Details
This is a "connection" page, showing publications WOLFGANG WINKELMAYER has written about Oligonucleotides.
WOLFGANG WINKELMAYER
Connection Strength
0.223
Oligonucleotides
  1. A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis. Kidney Int. 2024 07; 106(1):145-153.
    View in: PubMed
    Score: 0.223
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.